Not the news I was hoping for as I'm waiting for more material type announcements with large revenue potential like Alodokter, Medgate ETC, however it is a positive step forward and if approved ResApp's technology for the first time will be utilised in the US which will give us a much better chance of obtaining FDA clearance for our DX medical software that uses no additional hardware to identify coughing signatures.
I am very confident that ResApp's Sleep Apnea technology will be approved as a screening tool by the FDA, especially when one considers that our results are better than Drowzle mobile software application which already has been approved in the United States... I'm also glad that we don't have to splash around anymore funds in order to perform a study on US soil...
This update is welcoming for the screening of sleep apnea although I really don't think it's going to bring in massive amounts of revenue, but it will contribute somewhat to our bottom line and every little bit counts right?! If FDA approval is granted I would expect further uptake or a possible acquisition to a larger player who has plenty of money to splash around to get the word out for people to actually use it, as opposed to our company with limited funds and resources...
Cheers
Red bar
- Forums
- ASX - By Stock
- RAP
- Ann: ResApp announces FDA 510(k) submission for SleepCheckRx
Ann: ResApp announces FDA 510(k) submission for SleepCheckRx, page-11
Currently unlisted. Proposed listing date: 4 SEPTEMBER 2024 #
-
- There are more pages in this discussion • 64 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)